Follow up Study of HBV-induced Decompensated Cirrhosis Treated with Nucleot(s)ide Analogues

Objective To observes the efficacy of the four nucleot(s)ide analogues including lamivudine,adefovir,entecavir and telbivudine in treatment of HBV-induced decompensated cirrhosis.Methods Patients with HBV-induced decompensated hepatitis B cirrhosis treated with and without nucleot(s)ide analogues(NAs) were followed up for a median of 11 months.HBV DNA,liver function,Child-Pugh-Turcotte scores,and MELD scores.Results A total of 52 patients were enrolled in this study after excluding 59 patients out of 111 patients with HBV-induced decompensated hepatitis B cirrhosis.Forty patients were assigned into the NAs group and 12 patients into the control group.In the control group,the HBV DNA,ALT,AST,ALB,TBIL,CHE,INR,Child-Pugh scores and MELD scores had no improvement between as compared with the baseline values and the end-of-follow up values.In the NAs group,the HBV DNA,ALT,ALB,CHE,INR,Child-Pugh scores had significant improvement(P0.05) and AST,TBIL,MELD scores had no improvement(P0.05).Conclusion Nucleot(s)ide analogues could suppress HBV replication,improve liver function,stabilize or even reverse the development of decompensated cirrhosis and be well-tolerated.Further studies are needed to observe the long-term efficacy and the rate of liver cancer development.